Efectos circulatorios

ECG cuantitativo, análisis de fase ventricular izquierda, presión arterial, hemodinámica central y cerebral — documentación instrumental de respuestas cardiovasculares a la hirudoterapia

Last Updated: March 5, 2026Reviewed by: Andrei Dokukin, MD

Instrumental Evidence Profile

This page presents the most comprehensive instrumental assessment of cardiovascular hirudotherapy effects in the published literature — encompassing quantitative planimetric electrocardiography (validated against coronary angiography at 96.87% accuracy), polycardiographic left ventricular phase analysis, serial arterial blood pressure monitoring across >1,200 patients, echocardiographic ejection fraction measurement, rheoencephalography, and transcranial Doppler cerebral blood flow assessment. Evidence level: III (prospective studies with controls). These applications are not included in the FDA 510(k) clearance for medicinal leeches. Published research is presented for educational and scientific purposes.

International Clinical Evidence

The following evidence reflects international clinical experience. Practice standards, regulatory frameworks, and levels of evidence vary by jurisdiction. U.S. practitioners should refer to FDA guidance and applicable state regulations.

The cardiovascular effects of hirudotherapy bridge mechanistic pharmacology to clinical outcomes through objective instrumental documentation. Unlike subjective symptom assessment, the data presented here derive from electrocardiographic area calculations (validated against the gold standard of coronary angiography), polycardiographic phase timing, calibrated sphygmomanometry, echocardiographic volume measurements, and rheoencephalographic impedance analysis. The following sections demonstrate that hirudotherapy produces measurable, statistically significant improvements in cardiac electrical activity, myocardial contractile function, arterial blood pressure, and both central and cerebral hemodynamics.

Key finding across all modalities: Hirudotherapy operates as a corrective intervention — it corrects abnormal parameters without displacing normal values. Elevated blood pressure decreases; normal blood pressure is unchanged. Hyperkinetic cardiac output decreases; hypokinetic cardiac output increases. This bidirectional correction distinguishes hirudotherapy from unidirectional pharmacologic agents and is consistent with the corrective hemostatic model established for coagulation parameters.

Last updated: March 14, 2026

ECG planimétrico cuantitativo — Metodología

Standard qualitative ECG analysis is universally used in CAD diagnosis. The quantitative planimetric method — developed by Stamboltsyan and Mikhaelyani (1967) — extends diagnostic capability by measuring the actual area of ventricular complex components. The technique involves fivefold photographic enlargement of the ECG complex onto graph paper, with direct cell counting to calculate areas in mm². After reduction by a factor of 25, the true area is obtained.

Method Details

Area convention: Positive (+) if waveform lies above the isoelectric line; negative (−) if below. Biphasic T waves are summed algebraically
Portions measured: Initial (QRS complex) and terminal (ST segment + T wave) calculated separately
Precordial averaging: Mean ST-T area = (V1+V2+V3+V4+V5+V6) ÷ 6. Right precordial = (V1+V2+V3) ÷ 3. Left precordial = (V4+V5+V6) ÷ 3
Pathological threshold: Individual values compared to healthy subject reference ± 2 SD
Tape speed: 50 mm/s for optimal complex resolution

Reference Values — 35 Healthy Subjects (Ages 35–60)

Lead Group	Mean ST-T (mm²)	± SD
Right precordial (V1–V3)	13.2	± 4.536
Left precordial (V4–V6)	13.0	± 5.882
All 6 precordial leads	13.1	± 5.409

Isakhanyan (1991). Reference population: ages 35–60, no CAD.

The ST-T area serves as a sensitive "barometer" of myocardial perfusion, reflecting the smallest changes in coronary blood flow. Quantitative calculations detect trends toward increase or decrease in ST-T values that are not apparent from qualitative visual inspection alone. The value of this method has been demonstrated in diagnosing subclinical CAD manifestations (Isakhanian, 1976–1982), differentiating infectious-allergic myocarditis from CAD (Isakhanian, 1981), and monitoring therapeutic efficacy (Stamboltsyan et al., 1970).

Validación contra angiografía coronaria — n = 32

Gelshtein & Isakhanyan (1984) — Quantitative ECG vs Selective Coronary Angiography

32 patients with angina pectoris undergoing CABG. Comparison of qualitative ECG, quantitative planimetric ECG, and selective coronary angiography (gold standard).

Parameter	Qualitative ECG	Quantitative ECG	p
Diagnostic accuracy	81.25 ± 7.17%	96.87 ± 3.07%	<0.01
False negatives	6 patients	1 patient	—
Localization accuracy	28.12 ± 7.94%	65.62 ± 8.31%	<0.01

The quantitative method permitted clarification of coronary disturbance localization in one-third of cases where qualitative analysis failed. Precordial leads showed greatest diagnostic sensitivity — fluctuations in ST-T areas were identified more frequently and with greater amplitude deviation from normal in precordial leads.

Respuesta ECG de sesión única — n = 40 pacientes con EAC

Protocol: 5–6 ML applied to the left anterolateral chest wall (precordial region). Triple control recordings obtained the preceding day (9:00, 11:00, 13:00) with all therapeutic interventions suspended to establish intraday variability baseline. Treatment day: baseline ECG → ML application → ECG immediately after detachment → 1.5 h → 3 h. All other therapies suspended during study period.

Quantitative ECG Parameter Changes — Single ML Application (Isakhanyan, 1991)

ECG Area	Control (M ± m)	Immediately After	1.5 h Later	3 h Later
Mean ST-T, 6 precordial leads (mm²)	15.47 ± 8.41	35.01 ± 8.49 (p<0.05)	40.27 ± 8.39 (p<0.05)	21.11 ± 4.26 (p>0.5)
Mean ST-T, left precordial (mm²)	−21.47 ± 5.72	−16.73 ± 3.12 (p<0.05)	−7.02 ± 5.73 (p<0.05)	−21.71 ± 5.85 (p>0.1)

2.6×

ST-T area increase

40/40

Positive response rate

~1.5 h

Peak effect time

Qualitative T-Wave Changes

Qualitative T-wave changes in V5 and V6 were present in all 40 patients at baseline. TV4 was normal in only 3 cases. At 1.5 h post-detachment, TV5 became positive in 4 patients. Observed transition patterns:

Negative → biphasic → flat → positive
Biphasic → flat or positive
Small positive → larger positive
ST-segment restoration in 5/10 patients with baseline deviation

Intraday Control Validation

Triple control recordings (9:00, 11:00, 13:00 the preceding day, all therapies suspended) showed only minor physiological fluctuations within normal range. This establishes that the 2.6-fold ST-T increase and left precordial improvement following hirudotherapy exceeded normal intraday variability and are attributable to the therapeutic intervention rather than spontaneous variation.

Interpretation: The positive quantitative ECG response signifies coronary vasodilation through a cutaneous-visceral reflex pathway. The therapeutic stimulus applied from the cardiac reflex zone (precordial area, corresponding to dermatomes C2–C5 and Th1–Th5) selectively dilates coronary vessels. The left precordial leads demonstrated greater sensitivity, consistent with the predominant localization of pathology in the anterolateral and apical walls.

Respuesta ECG del curso de tratamiento — n = 18 pacientes con EAC

Landmark Quantitative Finding

A 3-session treatment course produced the most significant finding on this page: complete reversal of left precordial ST-T areas from pathological (−27.98 mm²) to normal (+4.23 mm²), p<0.001. This transition signifies conversion from impaired to normal coronary perfusion of the anterolateral and apical walls of the left ventricle.

Quantitative ECG Dynamics During Treatment Course (Isakhanyan, 1991)

ECG Area	Before Treatment	After 1st Session	After 2nd Session	After Course
Mean ST-T, 6 leads (mm²)	21.71 ± 7.43	52.90 ± 8.46 (p<0.05)	55.93 ± 8.57 (p<0.05)	56.89 ± 8.78 (p<0.02)
Mean ST-T, left precordial (mm²)	−27.98 ± 5.27	−14.97 ± 4.32 (p<0.05)	−10.07 ± 4.07 (p<0.05)	+4.23 ± 3.98 (p<0.001)

The reversal from −27.98 to +4.23 mm² represents a transition from pathological to normal coronary perfusion. The six-lead mean showed progressive improvement: 21.71 → 52.90 → 55.93 → 56.89 mm², with the greatest gain after the first session and sustained improvement through the course.

Qualitative T-Wave Evolution During Course — 54 T Waves Tracked

In 18 patients, 54 T waves (3 precordial leads × 18 patients) were tracked across control and three treatment sessions:

Pathological T waves in left precordial leads decreased progressively through sessions I, II, and III
TV4: Negative in 10 patients at baseline → 5 after first session → 6 after course (with T-wave amplitude improvement in remaining)
TV5: Negative in 11, small positive in 6 at baseline → after course: negative in 6, flat/weakly positive in 10
ST-segment deviation: Present in 5/18 at baseline; fully or partially restored in 3 after course
Transition pattern: Negative → biphasic → flat → positive (each step indicating improved coronary perfusion)

Qualitative analysis detected clinical improvement but did not provide the complete picture — the quantitative method revealed improvements in cases where T-wave polarity remained unchanged but amplitude shifted.

Evaluación de infarto agudo de miocardio — n = 15

Individual Lead Analysis in Acute MI (Isakhanyan, 1991)

In the acute MI subgroup (n = 15), averaged precordial values were not used because the direction of ST-T deviations in precordial leads is frequently inconsistent depending on the location of the myocardial injury zone — areas of opposite sign cancel out and distort the picture. Instead, area curves were constructed for each precordial lead individually.

Results: The positive quantitative response to hirudotherapy manifested as a tendency toward restoration of the intermediate (RS-T interval) and terminal (T wave) portions of the ventricular complex. This indicates that hirudotherapy reduces the degree of both myocardial ischemia (T-wave restoration) and injury (ST-segment restoration). The pathological Q wave — indicating prior necrosis — was not expected to change with treatment.

Important Consideration

Improved myocardial contractility increases oxygen demand, which may exacerbate oxygen deprivation during the acute phase of MI. The potential for increased myocardial oxygen demand during HT-induced contractility improvement must be carefully balanced against the benefit of improved perfusion. This application requires further study with modern assessment tools including serial troponin monitoring, continuous telemetry, and echocardiographic evaluation of wall motion abnormalities.

Análisis de fase ventricular izquierda — Método policardiográfico

Prior to these studies, no published investigations had analyzed changes in myocardial contractile function during hirudotherapy. Phase analysis of left ventricular systole was performed using the polycardiographic (PCG) method: simultaneous recording of ECG (standard lead II), phonocardiogram from the cardiac apex, and sphygmogram from the carotid artery. Systolic phases measured: Q-first heart sound interval, isometric contraction phase, ejection phase, mechanical systole, electrical systole, and Karpman's intrasystolic index (ISI = ejection phase ÷ mechanical systole × 100%).

Reference Values — 25 Healthy Subjects (Isakhanyan, 1991)

Phase	Range (s)	M	± m
Q – first heart sound	0.05 – 0.08	0.064	0.003
Isometric contraction phase	0.02 – 0.06	0.040	0.058
Ejection phase	0.24 – 0.30	0.265	0.011
Mechanical systole	0.25 – 0.36	0.327	0.005
Electrical systole	0.33 – 0.36	0.380	0.077
E-M systole difference	0.02 – 0.09	0.056	0.01
Cardiac cycle (R–R)	0.66 – 1.06	0.820	0.014
Karpman's ISI (%)	75.0 – 88.0	81.00	1.449

Single Session — n = 27

Contractile function impaired in 17/27 at baseline. After a single application of 5 ML to the precordial area:

Restoration in 10 patients (37% immediate response rate)
Q-first heart sound: prolonged in 5 → 3 at 1.5 h
Isometric contraction: pathological in 7 → 3 at 3 h
Ejection phase: deviated in 12 → restored in 4
Karpman's ISI: restored in 6 patients

Peak improvement at ~1.5 h, paralleling ECG improvement kinetics.

Treatment Course — n = 15

Baseline impairment in 9/15. Three sessions, average 5 ML per session to precordial area:

Ejection phase: restored in 6/6 (100% of those with baseline abnormality)
Isometric contraction: restored in 2 patients
Overall improvement in 5 patients
Worsening in 1 patient (slight deviation in isometric contraction phase and Karpman's ISI)
Unchanged in 3 patients (impaired before and after)

The complete ejection phase restoration rate (6/6) is notable, though subgroups were too small for formal statistical analysis.

Presión arterial — Evidencia en más de 1.200 pacientes

Treatment of hypertension with leeches has been practiced since the mid-20th century (Bottenberg, 1935–1983; Zaslavskaya, 1940; Lukashev, 1948; Galkin, 1956; Dotsenko, 1956). Interest has resurged with modern controlled studies. The evidence base encompasses more than 1,200 patients across five major studies.

Blood Pressure Studies — Comprehensive Evidence

Study	Year	n	Design	Key Finding	Level
Yena	1998	46	Prospective	SBP −57.8, DBP −26.0 mmHg. Sustained at 4 months (p<0.05)	III
Sidorov, Gileva et al.	2003	141	Controlled	61.9% significant BP decrease; 28.6% transient elevation; controls: no change	IIb
Sekretova & Kulagin	2003	1,020	Large case series	HT as leading treatment for stage III HTN with arrhythmia + CHF. No initial elevation	III
Kamenev et al.	2001	NR	Prospective	SBP 136.6→126.1 (p<0.05); DBP 88.3→75.1 (p<0.05)	III
Isakhanyan	1991	47	Two-group comparison	Hypertensive: SBP ↓ p<0.05. Normal BP: unchanged — corrective model	III

Key Finding: Corrective Model

Hirudotherapy lowers elevated blood pressure but does not lower normal baseline blood pressure. This was demonstrated by Isakhanyan (1991) in a two-group comparison: Group 1 (n=18, CAD + hypertension) showed significant SBP reduction at 1.5 h (p<0.05); Group 2 (n=29, CAD + normal BP) showed no blood pressure lowering. The corrective model is consistent with the corrective hemostatic pattern documented for coagulation parameters and distinguishes hirudotherapy from pharmacologic antihypertensive agents that lower BP regardless of baseline status.

Aplicación precordial vs. hepática — Dos mecanismos distintos

Precordial Route — Neural Vasodilation

Mechanism: Reflex (cutaneous-visceral) pathway. Therapeutic stimulus applied from the cardiac reflex zone (precordial area, dermatomes C2–C5 and Th1–Th5) selectively dilates coronary and peripheral vessels.

n = 18 (CAD + hypertension)
SBP reduction significant at 1.5 h (p<0.05)
DBP reduction: not statistically significant
Primary target: coronary perfusion improvement
Sustained systolic effect, limited diastolic response

A prolonged, substantial BP reduction should not be expected when ML are applied outside the reflex zone for hypertension (the mastoid process area).

Hepatic Route — Volume Reduction

Mechanism: Prolonged bleeding + bloodletting + reflex effect on the liver → improved hepatic circulation → decreased venous congestion and edema → reduced circulating blood volume → increased blood flow velocity → systemic circulation unloading.

BP	Before	After	p
SBP (mmHg)	172.00 ± 8.54	144.17 ± 5.67	<0.02
DBP (mmHg)	98.33 ± 4.07	80.83 ± 2.32	<0.001

n = 12 patients with hypertension + CHF I–III. 5–6 ML to right hypochondrium, 3 sessions, 4–5 day intervals. Liver size reduced by ≥1 cm during treatment itself (within 60–90 min).

Clinical implication: The two mechanisms are complementary. Precordial application acts primarily through neural vasodilation; hepatic application through volume reduction and hemodynamic unloading. The hepatic route produces more robust reductions in both SBP and DBP, particularly in patients with congestive heart failure where volume overload is the predominant pathophysiological driver. The primary reflex zone for arterial hypertension is the mastoid process area (Galkin, 1956; Dotsenko, 1956; Starodubskaya, 1998; Deryabin et al., 1999).

Application Sites for Hypertension — Site-Dependent Efficacy

Site	Primary Mechanism	References
Mastoid processes (primary)	Neural reflex antihypertensive	Galkin 1956, Dotsenko 1956, Starodubskaya 1998, Deryabin 1999
Hepatic (right hypochondrium)	Volume reduction, systemic unloading	Isakhanyan 1991, Skopichenko 1966
Precordial area	Coronary vasodilation (limited BP effect)	Isakhanyan 1991
Periauricular area	Neural reflex (alternative)	Zhuravsky et al. 1997
Temporal area	Neural reflex (alternative)	Bardasarova 1970, Bondareva 1998
Collar zone	Neural reflex (alternative)	Zadorova 1998

When ML are applied outside the mastoid processes, BP does not decrease in all patients and the reduction is of short duration (Galkin, 1956; Skopichenko, 1966; Bardasarova, 1973). This site-dependence supports the reflex mechanism.

Transient Hypertensive Response — Controversy & Evidence

Reports of Transient Elevation

Several authors reported at the VIII Conference of the Association of Hirudologists (November 2003, Moscow) that a slight or moderate rise in blood pressure was often observed immediately after ML application. The antihypertensive effect occurred after 30–60+ minutes.

Maksyutkina & Chekulaeva (2003) cautioned that patients with high baseline BP and vascular predisposition to hypertensive crises may develop serious complications — proposing that high-value arterial hypertension with crisis-prone course represents a relative contraindication.

Controlled Data Resolution

Methodological concerns: The cautionary reports had small samples, absent control groups, methods limited to BP measurement alone, no statistical analysis, and hypertension was not classified by etiology.

Higher-quality evidence: Sidorov et al. (2003; n=100+41 controls) demonstrated transient elevation in only 28.6% of patients (SBP +7.3%, DBP +4.9%). The Sekretova & Kulagin series (n=1,020) did not document initial BP elevation. The balance of evidence suggests the transient response is a minority phenomenon that does not negate the overall antihypertensive effect.

Comparison with venipuncture bloodletting: Both Lukashev (1948) and Ustinova (1969) documented that hirudotherapy lowers blood pressure for a longer period than conventional venipuncture bloodletting. This distinction may reflect the sustained pharmacologic action of SGS components — particularly the vasodilatory histamine-like compound and prostacyclin analogs — extending the hemodynamic effect beyond the duration attributable to volume depletion alone.

Central Hemodynamics — Bidirectional Correction

Bidirectional Hemodynamic Correction

In hypertensive patients, HT produces opposite hemodynamic corrections depending on the baseline variant: reducing cardiac output in hyperkinetic states and increasing cardiac output in hypokinetic states — both resulting in BP regulation but through opposite mechanisms. This bidirectional pattern, documented across coagulation parameters, cardiac hemodynamics, and cerebrovascular indices, represents a fundamental characteristic of hirudotherapy distinguishing it from unidirectional pharmacologic agents.

Hyperkinetic Variant (Gantimurova et al., 2001)

Baseline: Elevated cardiac output, normal or low peripheral resistance — BP elevation driven by increased stroke volume.

SI: 72.23 ± 2.59 → 61.78 ± 3.23 mL/m² (p<0.02) — decreased toward normal
CI: 4.97 ± 0.14 → 4.19 ± 0.3 L/min/m² (p<0.01) — decreased
Specific peripheral resistance: tendency to increase (compensatory response maintaining tissue perfusion)

→ BP decreased via reduced cardiac output

Hypokinetic Variant (Gantimurova et al., 2001)

Baseline: Depressed cardiac output, elevated peripheral resistance — BP elevation driven by high afterload.

SI: 32.75 ± 2.2 → 41.21 ± 2.3 mL/m² (p<0.02) — increased toward normal
CI: 2.02 ± 0.08 → 2.42 ± 0.14 L/min/m² (p<0.02) — increased
Elevated specific peripheral resistance: decreased significantly
Pulse pressure: increased

→ BP decreased via reduced afterload + improved forward flow

Yena (1998) — n = 46 Hypertensive Patients

ML applied to mastoid processes. Significant increase (p<0.05) in cardiac stroke volume. Decrease (p<0.05) in the minute volume index. Reduction (p<0.05) in total peripheral vascular resistance (TPVR). These findings indicate a hemodynamic shift toward a more efficient cardiac output pattern with reduced afterload. At 4-month follow-up, BP remained significantly reduced from baseline: SBP 178 ± 9.0 mmHg, DBP 100 ± 7.0 mmHg (p<0.05).

Pharmacotherapy Control Group (Gantimurova et al., 2001)

In the control group (n=10, pharmacological treatment only), no significant hemodynamic changes were observed. The absence of comparable hemodynamic improvement with pharmacotherapy alone suggests that hirudotherapy provides additive benefit beyond standard drug therapy for central hemodynamic optimization.

Cerebral Hemodynamics — Rheoencephalography & Transcranial Doppler

Rheoencephalographic Improvements (Gantimurova et al., 2001)

After a course of HT in hypertensive patients (n=59 main group), all rheoencephalographic parameters improved significantly:

Parameter	Right	Left	p
Rheographic index ↑	+60%	+63.6%	<0.001
Ascending limb time ↓	−18.2%	−15.6%	<0.01
Dicrotic index ↓	−15.6%	−19.2%	<0.05–0.01
Diastolic index ↓	−15.0%	−19.8%	<0.05

Comparison group (pharmacotherapy only): only ascending limb time reduction (14.3%, p<0.05). By end of treatment, rheographic index was significantly higher and dicrotic/diastolic indices significantly lower in the HT group vs controls.

Echocardiographic & Doppler Findings (Kamenev et al., 2001)

Patients with impaired central and cerebral hemodynamics. ML application with serial echocardiography and transcranial Doppler:

Parameter	Before	After	p
EF (%)	52.9 ± 9.1	66.4 ± 11.9	<0.05
HR (bpm)	67.2 ± 8.1	73.8 ± 13.2	<0.05
SBP (mmHg)	136.6 ± 13.1	126.1 ± 16.1	<0.05
DBP (mmHg)	88.3 ± 2.4	75.1 ± 17.3	<0.05

The EF increase from 52.9% to 66.4% represents a shift from borderline reduced to normal systolic function. Cerebral assessment: increased peak systolic velocity in extracranial and intracranial arteries, increased total cerebral blood flow and cerebral blood flow fraction of minute volume. Improved cerebral perfusion was mediated primarily by blood flow redistribution and vasodilation rather than increased cardiac output.

Heart Rate & Rhythm — Observations

Heart Rate Response Pattern

No significant, consistent heart rate changes were directly attributable to hirudotherapy. Observed variations likely reflect multiple competing physiological influences: patient anxiety (tachycardia), hemodynamic effect of blood loss (reflex tachycardia), and reduced heart failure severity from circulatory decompression (reflex bradycardia).

55 CAD patients: Pre-existing tachycardia in 13 patients. After ML treatment course: pulse slowing in 7, acceleration in 1, persisted in 5. Predominance of slowing (54%) in tachycardic patients is consistent with reduced sympathetic drive from hemodynamic burden relief
Confirmatory: Demin (1958a) noted pulse slowing after HT in patients with pre-existing tachycardia
Notable case: Zadorova (1998) described paroxysmal atrial fibrillation converting to normosystolic form after the first HT session, with full restoration of sinus rhythm after the second treatment. Mechanism may involve improved atrial perfusion, reduced atrial stretch, or autonomic modulation through the reflex pathway

This single case report suggests potential antiarrhythmic effects meriting prospective investigation.

Six Mechanistic Pathways — Integration with SGS Pharmacology

The cardiovascular effects documented on this page are attributable to multiple SGS-mediated pathways operating simultaneously:

1. Coronary Vasodilation

Cutaneous-visceral reflex from the precordial reflex zone. Therapeutic stimulus at dermatomes C2–C5 and Th1–Th5 selectively dilates coronary vessels. Documented by quantitative ECG: 2.6-fold ST-T area increase.

2. Anticoagulant & Antiplatelet

Hirudin-mediated thrombin inhibition and antiplatelet activity improve microcirculatory blood flow. See Chapter 9 for coagulation parameter documentation (APTT, fibrinogen, platelet aggregation).

3. Histamine-Like Vasodilation

SGS contains a histamine-like vasodilatory compound that enhances local and regional blood flow beyond the reflex pathway. Contributes to sustained antihypertensive effect exceeding simple bloodletting.

4. Prostacyclin-Like Activity

6-keto-PgF1α (prostacyclin analog) in SGS contributes to vasodilation and platelet inhibition. Extends the hemodynamic effect duration beyond volume depletion alone (Lukashev 1948, Ustinova 1969).

5. Hyaluronidase Enhancement

Tissue permeability increase facilitates SGS distribution into surrounding tissues. Acts as a "spreading factor" that amplifies the reach of other bioactive components beyond the immediate bite site.

6. Venous Decompression

Bloodletting and hepatic drainage reduce preload and afterload. Particularly effective in CHF: liver size reduction by ≥1 cm within 60–90 minutes, decreased venous congestion, improved cardiac function.

Representative Case Reports

Patient K.V., Age 56

Diagnosis: Hypertensive disease stage II, CAD, stable exertional angina FC II, CHF.

Baseline: BP 180/95–170/100 mmHg. ECG: negative "coronary" T waves in V4–V6, biphasic TII, ST depression in left precordial leads.

Treatment: 3 HT sessions (5 leeches each, precordial area).

Result: BP 175/90 mmHg. T waves flattened in precordial leads. Clear increase in ST-T area in left precordial leads. Reduced frequency of anginal episodes with improved subjective condition.

Patient L.S., Age 57

Diagnosis: CAD, stable exertional angina FC III, post-infarction ischemic cardiomyopathy (posterior wall and apex).

Treatment: 3 HT sessions (7, 5, and 8 leeches respectively).

Result: Considerably improved well-being with less frequent and shorter anginal episodes. TV4: negative → positive. TV5: negative → flattened. Progressive increase in ST-T areas through the treatment course.

Confirmatory Evidence — Additional Reports

Independent Confirmations of ECG and BP Improvement

Multiple independent investigators have confirmed the cardiovascular effects documented by the primary studies:

Demin (1958a), Aleshina (1959): ECG evidence of improved coronary circulation in CAD and hypertension after HT
Zadorova (1998), Deryabin et al. (1999): ECG improvement in CAD and arterial hypertension
Fedina & Korotygina (2001): Confirmed ECG-documented coronary circulation improvement
Gubin & Gubina (2001): Serial Holter monitoring and paired bicycle ergometry in stable angina FC I–III — reduction or disappearance of ischemic manifestations after HT

Recommended Instrumental Monitoring

Monitoring Protocol for Cardiovascular Hirudotherapy

Modality	When to Obtain	Parameters
12-lead ECG	Baseline, post-session (0, 1.5, 3 h), after course	ST-T morphology, T-wave evolution, quantitative planimetric analysis if available
Blood pressure	Baseline, q15 min × 1 h post-session	SBP, DBP; note any transient elevation (occurs in ~29% per Sidorov)
Echocardiography	Baseline, after course (optional)	EF, stroke volume, cardiac index, wall motion
Transcranial Doppler	Baseline, after course (if cerebral indications)	Peak systolic velocity, cerebral blood flow fraction
24-h Holter	Baseline, after course (if angina/arrhythmia)	Ischemic episodes, arrhythmia burden, ST changes

Complete Evidence Table — All Circulatory Studies

Circulatory system studies — instrumental cardiovascular assessments
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Isakhanyan 1991	Prospective single-arm with intraday controls	CAD patients without acute MI (n=40)	5–6 ML to precordial region, single session; ECG at 0, 1.5, 3 h	Quantitative planimetric ECG: mean ST-T area (6 precordial leads)	Mean ST-T area increased 2.6-fold (15.47→40.27 mm² at 1.5 h, p<0.05). Left precordial area improved from −21.47 to −7.02 mm² (p<0.05). Effect peaked at 1.5 h, returned to baseline by 3 h Triple intraday control recordings confirmed changes exceeded spontaneous variability
Isakhanyan 1991	Prospective treatment course	CAD patients — treatment course assessment (n=18)	3 sessions × 5 ML to precordial area, 3–5 day intervals	Quantitative ECG: mean ST-T area — serial course measurements	Left precordial ST-T reversed from −27.98 to +4.23 mm² (p<0.001). Six-lead mean increased from 21.71 to 56.89 mm² (p<0.02). Transition from pathological to normal coronary perfusion Most significant finding: reversal of pathological to normal values with cumulative treatment
Isakhanyan 1991	Prospective assessment with individual lead analysis	Acute myocardial infarction patients (n=15)	ML to precordial area; individual precordial lead ECG analysis	Quantitative ECG: ST-T improvement tendency per individual lead	Tendency toward restoration of ST-T complex. Reduced degree of both myocardial ischemia and injury markers. Individual lead analysis required due to cancellation artifacts with averaged values Individual lead analysis essential in acute MI due to variable injury zone location
Gelshtein & Isakhanyan 1984	Diagnostic validation study	Angina pectoris patients undergoing CABG (n=32)	Quantitative planimetric ECG vs selective coronary angiography	Diagnostic correspondence: qualitative vs quantitative ECG vs angiography	Qualitative ECG: 81.25% correlation with angiography (6 false negatives). Quantitative ECG: 96.87% (1 false negative, p<0.01). Localization accuracy: 28.12% qualitative vs 65.62% quantitative (p<0.01) Validated quantitative planimetric method as superior to qualitative ECG in CAD diagnosis
Isakhanyan 1991	Prospective polycardiographic assessment	CAD patients — single session (n=27)	5 ML to precordial area; polycardiographic phase analysis before and after	Left ventricular systolic phase restoration	Contractile function impaired in 17/27 at baseline. Restoration in 10 patients after single session. Isometric contraction: pathological in 7→3. Karpman ISI: restored in 6 patients. Peak improvement at 1.5 h First study of myocardial contractile function during hirudotherapy
Isakhanyan 1991	Prospective treatment course	CAD patients — LV phase analysis course (n=15)	3 sessions × 5 ML; serial polycardiographic assessment	LV systolic phase restoration over treatment course	Baseline impairment in 9/15. Ejection phase: restored in 6/6 (100% of those with baseline abnormality). Overall improvement in 5 patients. Worsening in 1 (isometric contraction phase deviation) Complete ejection phase restoration rate (6/6) notable
Yena 1998	Prospective assessment	Hypertensive patients (n=46)	ML to mastoid processes; serial BP + hemodynamic monitoring at 4 months	Blood pressure, stroke volume, TPVR	SBP reduced by 57.8 mmHg, DBP by 26.0 mmHg (p<0.05). At 4 months: BP 178±9.0/100±7.0 (significantly reduced from baseline). Stroke volume increased (p<0.05), TPVR decreased (p<0.05) Combined BP + hemodynamic documentation; sustained effect at 4 months
Sidorov, Gileva et al. 2003	Non-randomized controlled study	Hypertensive patients with pharmacotherapy controls (n=141)	HT (n=100) vs pharmacotherapy alone (n=41)	Blood pressure response pattern	Significant BP decrease in 61.9%. Transient elevation in 28.6% (SBP +7.3%, DBP +4.9%). Unchanged in 2 patients. Control group: no comparable hemodynamic changes Largest controlled hypertension study with HT. Documented transient elevation phenomenon
Sekretova & Kulagin 2003	Large case series — retrospective analysis	Stage III hypertension with arrhythmias, CHF > stage I (n=1020)	HT as primary treatment (spa contraindicated population)	Blood pressure reduction, clinical improvement	HT described as leading treatment method for this population. No initial BP elevation documented in this series. Effective in patients where conventional spa treatment was contraindicated Largest single-center hypertension series in hirudotherapy literature (n=1,020)
Isakhanyan 1991	Prospective two-group comparison	Group 1: CAD + hypertension (n=18); Group 2: CAD + normal BP (n=29) (n=47)	5–6 ML to precordial area, 3 sessions	Blood pressure response by baseline BP status	Group 2 (normal BP): HT does not lower baseline normal BP levels. Group 1 (hypertension): SBP reduction significant at 1.5 h (p<0.05); DBP reduction not significant. Selective antihypertensive effect Key finding: HT lowers elevated BP but does NOT lower normal BP — corrective model
Isakhanyan 1991	Prospective assessment	Hypertensive disease + cardiovascular disorders + CHF stage I–III (n=12)	5–6 ML to right hypochondrium (hepatic area), 3 sessions, 4–5 day intervals	Blood pressure reduction via hepatic application	SBP: 172.00±8.54 → 144.17±5.67 mmHg (p<0.02). DBP: 98.33±4.07 → 80.83±2.32 mmHg (p<0.001). Liver size reduced by ≥1 cm during treatment. Superior DBP reduction vs precordial route Hepatic route: volume reduction mechanism. DBP reduction (p<0.001) exceeds precordial route
Kamenev et al. 2001	Prospective echocardiographic + Doppler assessment	Patients with impaired central and cerebral hemodynamics (n=NR)	ML application; echo + transcranial Doppler pre/post-course	Ejection fraction, blood pressure, cerebral blood flow	EF: 52.9±9.1% → 66.4±11.9% (p<0.05). SBP: 136.6→126.1 (p<0.05). DBP: 88.3→75.1 (p<0.05). Increased peak systolic velocity in extracranial and intracranial arteries. Total cerebral blood flow increased EF improvement from borderline reduced to normal systolic function is clinically meaningful
Gantimurova et al. 2001	Non-randomized controlled study	Arterial hypertension — hemodynamic variant analysis (n=79)	HT (n=59 main group) vs pharmacotherapy (n=10 control) + 10 additional	Central hemodynamics by baseline hemodynamic variant; cerebral indices	Hyperkinetic: SI 72.23→61.78 (p<0.02), CI 4.97→4.19 (p<0.01). Hypokinetic: SI 32.75→41.21 (p<0.02), CI 2.02→2.42 (p<0.02). Rheographic index +60% right, +63.6% left (p<0.001). Controls: no significant hemodynamic changes Bidirectional correction: HT reduces elevated output AND increases depressed output. Pharmacotherapy controls showed no comparable effect
Gubin & Gubina 2001	Prospective with serial Holter and bicycle ergometry	Stable angina FC I–III (n=NR)	HT course; serial 24-h Holter monitoring + paired bicycle ergometry	Ischemic manifestations on Holter and exercise testing	Reduction or disappearance of ischemic manifestations after hirudotherapy course Confirmatory evidence using gold-standard ambulatory and exercise monitoring

GRADE Evidence Level: Moderate

RCTs with limitations or strong observational studies

Overall assessment: Level IIb–III evidence. Prospective studies with some controlled comparisons (Sidorov n=141, Gantimurova n=79 with controls). No randomized controlled trials. Consistent results across 14 independent studies spanning 1958–2003. Total patients assessed: >1,200 for blood pressure; 55 for quantitative ECG; 79 for central hemodynamics; 27 for LV phase analysis.

Evidence Summary — Key Quantitative Findings

Domain	Key Finding	n	p-value
ECG single session	2.6-fold mean ST-T area increase	40	<0.05
ECG treatment course	Left precordial reversal: −27.98 → +4.23 mm²	18	<0.001
Angiographic validation	96.87% diagnostic accuracy (quant. ECG vs angiography)	32	<0.01
LV contractility (single)	Return to baseline in 10/27 (37%) after single session	27	—
LV contractility (course)	Ejection phase: restored 6/6 (100%)	15	—
BP — hepatic route	SBP 172→144, DBP 98→81 mmHg	12	<0.001
BP — controlled	61.9% significant decrease (vs controls: no change)	141	sig
BP — largest series	HT as leading treatment, stage III HTN	1,020	—
Bidirectional correction	Hyperkinetic SI 72→62↓; Hypokinetic SI 33→41↑	79	<0.02
Ejection fraction	52.9% → 66.4% (borderline → normal)	NR	<0.05
Cerebral hemodynamics	Rheographic index +60–64% (vs controls: +14.3% only)	69	<0.001
Corrective model	Elevated BP lowered; normal BP unchanged	47	<0.05

Evidence Gaps & Research Priorities

The instrumental evidence presented here represents the most comprehensive cardiovascular assessment of hirudotherapy in the published literature. However, several critical gaps remain:

No randomized controlled trials (RCTs): All studies are prospective observational or non-randomized controlled. The Sidorov study (n=141) includes a control group but lacked randomization. Modern RCTs with standardized cardiovascular endpoints (MACE, hospitalization, mortality) are needed
Modern instrumentation replication: Many studies used analog-era recording equipment (photographic ECG enlargement, mechanical polycardiographs). Digital ECG with automated ST-segment analysis, cardiac MRI, and 3D echocardiography would strengthen the evidence base and enable comparison with standard cardiovascular drug therapy outcomes
Long-term follow-up: The Yena study (4-month data) is the longest follow-up. Cardiovascular outcomes require years of observation — studies with 1-year, 5-year, and 10-year follow-up are needed to establish whether the documented improvements translate into reduced cardiovascular events
Dose-response relationships: The optimal number of leeches, sessions, and intervals have not been systematically studied. Most protocols used 5–6 leeches per session with 3–5 day intervals, but this was empirically derived rather than dose-optimization studied
Mechanism attribution: The six mechanistic pathways operate simultaneously. Component-specific studies (e.g., isolated reflex stimulation vs SGS pharmacology vs volume depletion) would clarify mechanism contributions and enable targeted optimization
Safety in acute MI: The potential for increased myocardial oxygen demand during HT-induced contractility improvement requires careful investigation with serial troponin monitoring and continuous telemetry before acute MI applications can be recommended
Transient hypertensive response: The mechanism and clinical significance of the transient BP elevation reported in ~29% of patients (Sidorov et al.) needs prospective characterization — whether it predicts poor response, requires pre-treatment, or resolves spontaneously

ASH supports the development of randomized controlled trials with standardized cardiovascular endpoints (ECG, echocardiographic EF, ambulatory BP monitoring, MACE outcomes) to build upon the substantial instrumental evidence base and enable evidence-based integration with conventional cardiovascular therapy.